Capricor Therapeutics, Inc. (CAPR) Guidance & Earnings Results
On 2025-08-11 Capricor Therapeutics, Inc. reaffirmed guidance: "Cash runway into Q4 2026; no revenue…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CAPRCapricor Therapeutics, Inc.Follow CAPR — free
—
Price chart with a free account
- Market cap
- 344.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 17 Nov, in 24 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 11 Aug 25 | Reaffirmed | Cash runway into Q4 2026; no revenue guidance. |
Capricor Therapeutics, Inc. — questions
- What guidance did Capricor Therapeutics, Inc. give?
- On 2025-08-11: "Cash runway into Q4 2026; no revenue guidance."
- When does Capricor Therapeutics, Inc. report earnings?
- Capricor Therapeutics, Inc.'s next earnings report is expected on 2026-11-17.
Every figure on this page comes from Capricor Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.